The GRM7 gene, early response to risperidone, and schizophrenia

a genome-wide association study and a confirmatory pharmacogenetic analysis

E. Sacchetti, C. Magri, A. Minelli, P. Valsecchi, M. Traversa, S. Calza, A. Vita, M. Gennarelli

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The search for biomarkers of response to antipsychotic medications is hindered by difficulties inherent in the topic or related to persistent methodological difficulties, such as high rates of anticipated discontinuation and consequent distortions in the imputation of missing data. Because early response to antipsychotics represents a sufficiently reliable index of the subsequent treatment response in patients with schizophrenia, we undertook a real-world, genome-wide association study (GWAS) with the aim of identifying genetic predictors of response to risperidone after 2 weeks in 86 patients with schizophrenia. Limited to the associations reaching significance in the GWAS, confirmatory analysis relative to risperidone response over 9 months was also designed involving 97 patients (European only) enroled in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) genetic substudy. The GWAS revealed a significant association (false discovery rate 0.02) of the single-nucleotide polymorphism rs2133450 inside the GRM7 gene with Emsley’s positive domain derived from the positive and negative syndrome scale (PANSS). Patients with the rs2133450 CC genotype presented poorer improvement in the positive domain over 2 weeks, with odds ratios of 12.68 (95% CI, 3.51–45.76) and 6.95 (95% confidence interval (CI), 2.37–20.37) compared with patients with the AA and AC genotypes, respectively. Compared with A homozygotes, rs2133450 C homozygotes enroled in the CATIE-derived confirmatory analysis showed less improvement in Emsley’s positive, excited and depression domains, positive and general PANSS subtypes, and total PANSS after 9 months of treatment with risperidone. The original GWAS and the CATIE-derived confirmatory analysis support the proposal that the rs2133450 may have translational relevance as a predictor of response to risperidone.The Pharmacogenomics Journal advance online publication, 9 February 2016; doi:10.1038/tpj.2015.90.

Original languageEnglish
JournalPharmacogenomics Journal
DOIs
Publication statusE-pub ahead of print - Feb 9 2016

Fingerprint

Risperidone
Genome-Wide Association Study
Antipsychotic Agents
Schizophrenia
Genes
Homozygote
Clinical Trials
Genotype
Confidence Intervals
Genetic Engineering
Pharmacogenetics
Single Nucleotide Polymorphism
Publications
Biomarkers
Odds Ratio
Pharmacogenomic Testing
Depression
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

The GRM7 gene, early response to risperidone, and schizophrenia : a genome-wide association study and a confirmatory pharmacogenetic analysis. / Sacchetti, E.; Magri, C.; Minelli, A.; Valsecchi, P.; Traversa, M.; Calza, S.; Vita, A.; Gennarelli, M.

In: Pharmacogenomics Journal, 09.02.2016.

Research output: Contribution to journalArticle

@article{d9daf9c5f4204204ad5b5797d48a357a,
title = "The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis",
abstract = "The search for biomarkers of response to antipsychotic medications is hindered by difficulties inherent in the topic or related to persistent methodological difficulties, such as high rates of anticipated discontinuation and consequent distortions in the imputation of missing data. Because early response to antipsychotics represents a sufficiently reliable index of the subsequent treatment response in patients with schizophrenia, we undertook a real-world, genome-wide association study (GWAS) with the aim of identifying genetic predictors of response to risperidone after 2 weeks in 86 patients with schizophrenia. Limited to the associations reaching significance in the GWAS, confirmatory analysis relative to risperidone response over 9 months was also designed involving 97 patients (European only) enroled in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) genetic substudy. The GWAS revealed a significant association (false discovery rate 0.02) of the single-nucleotide polymorphism rs2133450 inside the GRM7 gene with Emsley’s positive domain derived from the positive and negative syndrome scale (PANSS). Patients with the rs2133450 CC genotype presented poorer improvement in the positive domain over 2 weeks, with odds ratios of 12.68 (95{\%} CI, 3.51–45.76) and 6.95 (95{\%} confidence interval (CI), 2.37–20.37) compared with patients with the AA and AC genotypes, respectively. Compared with A homozygotes, rs2133450 C homozygotes enroled in the CATIE-derived confirmatory analysis showed less improvement in Emsley’s positive, excited and depression domains, positive and general PANSS subtypes, and total PANSS after 9 months of treatment with risperidone. The original GWAS and the CATIE-derived confirmatory analysis support the proposal that the rs2133450 may have translational relevance as a predictor of response to risperidone.The Pharmacogenomics Journal advance online publication, 9 February 2016; doi:10.1038/tpj.2015.90.",
author = "E. Sacchetti and C. Magri and A. Minelli and P. Valsecchi and M. Traversa and S. Calza and A. Vita and M. Gennarelli",
year = "2016",
month = "2",
day = "9",
doi = "10.1038/tpj.2015.90",
language = "English",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The GRM7 gene, early response to risperidone, and schizophrenia

T2 - a genome-wide association study and a confirmatory pharmacogenetic analysis

AU - Sacchetti, E.

AU - Magri, C.

AU - Minelli, A.

AU - Valsecchi, P.

AU - Traversa, M.

AU - Calza, S.

AU - Vita, A.

AU - Gennarelli, M.

PY - 2016/2/9

Y1 - 2016/2/9

N2 - The search for biomarkers of response to antipsychotic medications is hindered by difficulties inherent in the topic or related to persistent methodological difficulties, such as high rates of anticipated discontinuation and consequent distortions in the imputation of missing data. Because early response to antipsychotics represents a sufficiently reliable index of the subsequent treatment response in patients with schizophrenia, we undertook a real-world, genome-wide association study (GWAS) with the aim of identifying genetic predictors of response to risperidone after 2 weeks in 86 patients with schizophrenia. Limited to the associations reaching significance in the GWAS, confirmatory analysis relative to risperidone response over 9 months was also designed involving 97 patients (European only) enroled in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) genetic substudy. The GWAS revealed a significant association (false discovery rate 0.02) of the single-nucleotide polymorphism rs2133450 inside the GRM7 gene with Emsley’s positive domain derived from the positive and negative syndrome scale (PANSS). Patients with the rs2133450 CC genotype presented poorer improvement in the positive domain over 2 weeks, with odds ratios of 12.68 (95% CI, 3.51–45.76) and 6.95 (95% confidence interval (CI), 2.37–20.37) compared with patients with the AA and AC genotypes, respectively. Compared with A homozygotes, rs2133450 C homozygotes enroled in the CATIE-derived confirmatory analysis showed less improvement in Emsley’s positive, excited and depression domains, positive and general PANSS subtypes, and total PANSS after 9 months of treatment with risperidone. The original GWAS and the CATIE-derived confirmatory analysis support the proposal that the rs2133450 may have translational relevance as a predictor of response to risperidone.The Pharmacogenomics Journal advance online publication, 9 February 2016; doi:10.1038/tpj.2015.90.

AB - The search for biomarkers of response to antipsychotic medications is hindered by difficulties inherent in the topic or related to persistent methodological difficulties, such as high rates of anticipated discontinuation and consequent distortions in the imputation of missing data. Because early response to antipsychotics represents a sufficiently reliable index of the subsequent treatment response in patients with schizophrenia, we undertook a real-world, genome-wide association study (GWAS) with the aim of identifying genetic predictors of response to risperidone after 2 weeks in 86 patients with schizophrenia. Limited to the associations reaching significance in the GWAS, confirmatory analysis relative to risperidone response over 9 months was also designed involving 97 patients (European only) enroled in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) genetic substudy. The GWAS revealed a significant association (false discovery rate 0.02) of the single-nucleotide polymorphism rs2133450 inside the GRM7 gene with Emsley’s positive domain derived from the positive and negative syndrome scale (PANSS). Patients with the rs2133450 CC genotype presented poorer improvement in the positive domain over 2 weeks, with odds ratios of 12.68 (95% CI, 3.51–45.76) and 6.95 (95% confidence interval (CI), 2.37–20.37) compared with patients with the AA and AC genotypes, respectively. Compared with A homozygotes, rs2133450 C homozygotes enroled in the CATIE-derived confirmatory analysis showed less improvement in Emsley’s positive, excited and depression domains, positive and general PANSS subtypes, and total PANSS after 9 months of treatment with risperidone. The original GWAS and the CATIE-derived confirmatory analysis support the proposal that the rs2133450 may have translational relevance as a predictor of response to risperidone.The Pharmacogenomics Journal advance online publication, 9 February 2016; doi:10.1038/tpj.2015.90.

UR - http://www.scopus.com/inward/record.url?scp=84957831630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957831630&partnerID=8YFLogxK

U2 - 10.1038/tpj.2015.90

DO - 10.1038/tpj.2015.90

M3 - Article

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

ER -